News on companion diagnostics and drug/test co-development.
Myriad filed an sPMA for myChoice CDx despite GSK's confidence that Zejula will be approved in newly diagnosed ovarian cancer regardless of biomarker status.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
AstraZeneca and Merck also announced they have filed for approval of Lynparza in patients who have mutations in more than a dozen homologous recombination repair genes.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
